The agency is missing deadlines and not responding to biotech companies, forcing some to push back clinical trials.

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the impact of mass layoffs at the FDA, impact on ...

The pharmaceutical industry's next billion-dollar blockbuster won't come from a lab alone—it will come from listening to ...

In recent weeks, biotech companies have faced setbacks in moving forward with clinical trials due to operational delays at the FDA, according to an exclusive report from The Wall Street Journal ...

Scale-up is a common problem encountered in all forms of development across industries, and oral solid dose manufacturing ...

When the Trump administration cut more than $11 billion in COVID-era funds to states, addiction recovery programs suffered swift losses.

GenAI offers a realistic path forward in tackling previously undruggable targets, with the potential to reshape the entire ...

Combining Trodelvy with Keytruda and pushing it into the frontline setting could “potentially double” the ADC’s market in ...

Gilead Sciences said a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women ...

Biotech companies developing drugs for hard-to-treat diseases and other ailments are being forced to push back clinical trials and drug testing in the wake of mass layoffs at the Food and Drug ...